Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy-Reference-Cited by-同舟云学术

Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy

Published:2019-07-19 Issue:1 Volume:10 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Niemann Julia,Woller Norman,Brooks Jennifer,Fleischmann-Mundt Bettina,Martin Nikolas T.,Kloos Arnold,Knocke Sarah,Ernst Amanda M.,Manns Michael P.,Kubicka Stefan,Wirth Thomas C.,Gerardy-Schahn Rita^ORCID,Kühnel Florian^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-019-11137-5.pdf

Reference69 articles.

1. Russell, S. J., Peng, K. W. & Bell, J. C. Oncolytic virotherapy. Nat. Biotechnol. 30, 658–670 (2012).

2. Benencia, F., Courreges, M. C., Fraser, N. W. & Coukos, G. Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol. Ther. 7, 1194–1205 (2008).

3. Errington, F. et al. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther. 15, 1257–1270 (2008).

4. Breitbach, C. J. et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 15, 1686–1693 (2007).

5. Senzer, N. N. et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 27, 5763–5771 (2009).

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy;Nature Protocols;2024-05-20

2. Oncolytic adenovirus encoding apolipoprotein A1 suppresses metastasis of triple-negative breast cancer in mice;Journal of Experimental & Clinical Cancer Research;2024-04-03

3. Immune landscape and response to oncolytic virus-based immunotherapy;Frontiers of Medicine;2024-03-08

4. Viral therapy for targeted drug delivery to cancers: Recent advances, clinical and regulatory perspectives;Journal of Drug Delivery Science and Technology;2024-02

5. PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma;Cancer Cell International;2024-01-30